🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

COVID-19 Coagulopathy Extension Study

Recruitingn/aAges 18 Years - 99 YearsAllUniversity of Iowa
NCT05334615 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

At the University of Iowa, the investigators led a multicenter randomized clinical trial comparing standard prophylactic dose to intermediate dose enoxaparin in hospitalized patients with COVID-19 (NCT04360824). As part of an exploratory biomarker component of this trial, blood samples were collected from hospitalized COVID-19 patients at enrollment and weekly for up to 30 days of hospitalization. The pilot results, as well as reports from other groups, demonstrate increased potential for thrombin generation in the plasma of COVID-19 patients. In particular, in the COVID-19 patient cohort enhanced thrombin generation potential persisted for at least 30 days of hospitalization. The investigators now propose to explore the mechanistic roles of activation of blood cells (such as platelets and neutrophils) and products of cellular activation as mediators of enhanced thrombin generation in pa

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria Subjects must meet all inclusion criteria in one of the following three categories: 1. Acute COVID-19 * Hospital admission for management of symptoms related to COVID-19 * Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission * Age ≥18 years 2. Incidental COVID-19 * Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2 * Age ≥18 years 3. Acute influenza * Hospital admission for clinical management of symptoms related to influenza * Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission * Negative testing for SARS-CoV-2 * Age ≥18 years Exclusion criteria * Current pregnancy * Prisoner * History of a bleeding disorder * Active cancer
💊

What it tests

  • Not listed
📍

Where

1 site
University of Iowa Health Care
Iowa City, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy